Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

Latanoprostene bunod (LBN) 0.024%, a modified prostaglandin analog, was approved on November 2, 2017, for the reduction of IOP in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). LBN works by combining the IOP-lowering effects of the prostaglandin analogs (through the uveosclera...

Descripción completa

Detalles Bibliográficos
Autores principales: Addis, Victoria M, Miller-Ellis, Eydie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304237/
https://www.ncbi.nlm.nih.gov/pubmed/30587912
http://dx.doi.org/10.2147/OPTH.S156038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304237/
https://www.ncbi.nlm.nih.gov/pubmed/30587912
http://dx.doi.org/10.2147/OPTH.S156038

Ejemplares similares